. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Cancer Prev Res (Phila). 2011 Sep 19;4(12):2072–2082. doi: 10.1158/1940-6207.CAPR-11-0300

Table 3.

Association of ODC haplotypes with risk for adenoma recurrence, Aspirin/Folate Polyp Prevention Study, 1994–2001

Haplotype	Frequency (%) Controls/Cases	RR (95% CI)	P^a	P^b
Block 1^c
TCG	47.2 / 41.6	1.00 (reference)		0.011
GCA	23.1 / 25.5	1.14 (1.00–1.30)	0.06
GCG	21.0 / 19.2	1.02 (0.88–1.17)	0.84
GTG	8.5 / 13.0	1.33 (1.12–1.57)	0.001
Rare	0.2 / 0.7	1.41 (0.70–2.81)	0.34
Block 2^d
GCCT	33.3 / 37.3	1.00 (reference)		0.012
GCCC	31.0 / 29.7	0.91 (0.80–1.05)	0.20
CCCT	25.2 / 21.4	0.85 (0.73–0.98)	0.029
CCTT	7.3 / 5.8	0.82 (0.64–1.04)	0.11
GTCC	2.7 / 5.7	1.27 (1.01–1.61)	0.044
Rare	0.4 / 0.1	0.55 (0.13–2.32)	0.41
Block 3^e
TG	66.1 / 64.3	1.00 (reference)		0.63
TA	23.7 / 25.3	1.05 (0.93–1.20)	0.41
CG	10.2 / 10.4	1.06 (0.89–1.27)	0.50
Block 4^f
GAAG	46.4 / 41.9	1.00 (reference)		0.19
CAAA	23.8 / 28.9	1.17 (1.02–1.33)	0.021
CGAG	21.4 / 20.1	1.02 (0.88–1.18)	0.81
CAGA	7.3 / 7.4	1.06 (0.86–1.31)	0.57
Rare	0.9 / 1.6	1.27 (0.86–1.31)	0.33

Abbreviations: RR, relative risk; CI, confidence interval

Per haplotype relative risk and Wald test P-value adjusted for age and sex.

Likelihood ratio test P-values for joint test of all haplotypes in the block.

Block 1 includes rs13000916, rs11694911 and rs2430419.

Block 2 includes rs818162, rs1049500, rs28362416 and rs7559979.

Block 3 includes rs28362380 and rs2302615.

Block 4 includes rs1728148, rs885815, rs2884211 and rs2357551.